Literature DB >> 33612190

Letting the sun shine on patient voices: Perspectives about medications for opioid use disorder in Florida.

Amanda Sharp1, Melissa Carlson2, Veronica Howell2, Kathleen Moore2, Zev Schuman-Olivier3.   

Abstract

The 2017 declaration of the opioid overdose epidemic as a public health emergency in the United States enhanced a national focus on effective and sustainable treatments for opioid use disorder (OUD), including multiple options utilizing medication. Despite clinical studies demonstrating efficacy, numerous reports suggest that medication for opioid use disorder (MOUD) has been underutilized, leaving many questions about specific barriers and facilitators. This study examines factors impacting attitudes and perspectives related to MOUD that influence its utilization and acceptance in a state where support for harm reduction and treatment policy has been limited. With consideration for the contextual cultural factors of this region, we conducted twelve individual interviews with people seeking treatment for OUD at a detoxification facility in Tampa, Florida. This study called attention to the perspectives of patients regarding their unique self-identified needs and beliefs around MOUD as it relates to their addiction treatment. We evaluated the perspectives collected in the interviews (N = 12) based on three main themes: 1) positive perceptions of MOUD; 2) negative perceptions of MOUD; and 3) overall perceptions of treatment and recovery. Findings suggest that participants' varying levels of positive and negative perspectives about MOUD are informed by nuances in their social networks and varying levels of exposure or education. For example, participants held more negative opinions of MOUD than positive, accounting mostly for a view that it serves as a direct substitute for illicit opioids rather than a sustainable or supportive solution addressing the underlying causes of addiction. These opinions may be largely dependent on geographic location that dictates policy, practice, funding, and, in turn, cultural acceptance of MOUD. The findings in this qualitative study may help to inform future education efforts, initiatives addressing patient-level concerns, and provide decision-makers with meaningful information to tailor programmatic policy and procedures specific to local area social inputs and resource exposure.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Detoxification; Medication for opioid use disorder (MOUD); Medication-assisted treatment (MAT); Opioid use disorder; Patient perspectives

Year:  2020        PMID: 33612190      PMCID: PMC8128038          DOI: 10.1016/j.jsat.2020.108247

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  45 in total

1.  Adoption and implementation of medications in addiction treatment programs.

Authors:  Hannah K Knudsen; Amanda J Abraham; Paul M Roman
Journal:  J Addict Med       Date:  2011-03       Impact factor: 3.702

2.  Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation.

Authors:  Paul M Roman; Amanda J Abraham; Hannah K Knudsen
Journal:  Addict Behav       Date:  2011-01-27       Impact factor: 3.913

3.  Exploring the Concepts of Abstinence and Recovery Through the Experiences of Long-Term Opiate Substitution Clients.

Authors:  Caitlin Notley; Annie Blyth; Vivienne Maskrey; Hayley Pinto; Richard Holland
Journal:  Subst Abus       Date:  2014-08-15       Impact factor: 3.716

4.  Medication-assisted therapies--tackling the opioid-overdose epidemic.

Authors:  Nora D Volkow; Thomas R Frieden; Pamela S Hyde; Stephen S Cha
Journal:  N Engl J Med       Date:  2014-04-23       Impact factor: 91.245

5.  Medications For Addiction Treatment: Changing Language to Improve Care.

Authors:  Sarah E Wakeman
Journal:  J Addict Med       Date:  2017 Jan/Feb       Impact factor: 3.702

6.  Barriers to Medications for Addiction Treatment: How Stigma Kills.

Authors:  Sarah E Wakeman; Josiah D Rich
Journal:  Subst Use Misuse       Date:  2017-09-29       Impact factor: 2.164

7.  Client and counselor attitudes toward the use of medications for treatment of opioid dependence.

Authors:  Traci Rieckmann; Marilyn Daley; Bret E Fuller; Cindy P Thomas; Dennis McCarty
Journal:  J Subst Abuse Treat       Date:  2006-12-08

8.  Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.

Authors:  Yih-Ing Hser; Andrew J Saxon; David Huang; Al Hasson; Christie Thomas; Maureen Hillhouse; Petra Jacobs; Cheryl Teruya; Paul McLaughlin; Katharina Wiest; Allan Cohen; Walter Ling
Journal:  Addiction       Date:  2013-10-09       Impact factor: 6.526

9.  A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder.

Authors:  Maria A Sullivan; Adam Bisaga; Martina Pavlicova; Kenneth M Carpenter; C Jean Choi; Kaitlyn Mishlen; Frances R Levin; John J Mariani; Edward V Nunes
Journal:  Am J Psychiatry       Date:  2018-10-19       Impact factor: 18.112

10.  Stigma: how it affects the substance use disorder patient.

Authors:  Janet Zwick; Hannah Appleseth; Stephan Arndt
Journal:  Subst Abuse Treat Prev Policy       Date:  2020-07-27
View more
  1 in total

1.  Recruitment into a Clinical Trial of People Living with Uncontrolled HIV Infection Who Inject Drugs: a Site Case Report from the CTN 67 CHOICES Study.

Authors:  Hansel Tookes; Jessica Ucha; Allan E Rodriguez; Edward Suarez; Elizabeth Alonso; Lisa R Metsch; Daniel J Feaster; Tyler S Bartholomew; Kim A Hoffman; P Todd Korthuis
Journal:  J Behav Health Serv Res       Date:  2021-09-29       Impact factor: 1.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.